Olema Pharmaceuticals, Inc. Share Price & Technical Analysis
OLMA · $13.68 (-2.70%)
Healthcare / Biotechnology
$13.68
-2.70%
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-5% return in May, 3% avg return in past 3 year May month.
-40% return in 2026, 151% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 3% | 3% | -37% | -5% | -5% | – | – | – | – | – | – | – | -40% |
| 25 | 3% | -25% | -14% | 41% | 4% | -19% | 21% | 8% | 78% | -9% | 214% | -9% | 293% |
| 24 | -7% | -5% | -11% | -9% | -4% | 2% | 50% | -27% | -1% | -3% | -13% | -45% | -73% |
| 23 | 92% | -15% | -17% | 37% | 8% | 73% | -2% | 17% | 22% | 10% | 5% | 1% | 232% |
| 22 | -34% | -29% | -9% | -42% | 12% | 41% | 22% | -20% | -30% | 36% | -26% | -14% | -92% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.18B
P/E ratio
—
52W high
$36.26
52W low
$3.89
Volume
10,67,377
Beta
2.06
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Olema Pharmaceuticals, Inc. share price today?
- Olema Pharmaceuticals, Inc. (OLMA) last traded around $13.68 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does OLMA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OLMA. Download the app for real-time alerts.
- How can I analyze Olema Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.